ASCENTAGE PHARMA GROUP INTERNATIONAL Business Summary

Ascentage Pharma Group International (AAPG) is a global, commercial-stage biopharmaceutical company specializing in the discovery and development of apoptosis-modulating small molecules. The company generates revenue primarily through the commercial sale of its proprietary oncology therapies, most notably Olverembatinib (HQP1351)—the first third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia—and Lisaftoclax (APG-2575), a Bcl-2 selective inhibitor. Its business model is further supported by strategic licensing agreements and global clinical collaborations, such as its high-profile partnership with Takeda. The company operates through a single reportable segment focused on therapies for hematological malignancies, solid tumors, and age-related diseases, leveraging a deep pipeline of inhibitors targeting protein-protein interactions (PPIs) like MDM2-p53 and IAP. Within the competitive landscape, Ascentage contends with major oncology and biotech players including BeiGene, Arrowhead Pharmaceuticals, and Jazz Pharmaceuticals; it distinguishes itself as a pioneer in the apoptosis-targeted therapy niche, specifically holding a first-mover advantage in the Chinese market for next-generation kinase and Bcl-2 inhibitors. Founded in 2009 by Dr. Dajun Yang, Dr. Shaomeng Wang, and Dr. Ming Guo, the company is led by Chairman and CEO Dr. Dajun Yang, a veteran researcher with over 30 years in oncology who previously co-founded Ascenta Therapeutics. The executive team includes Chief Medical Officer Dr. Yifan Zhai, formerly of the National Cancer Institute (NCI), and Chief Financial Officer Dr. Veet Misra, who brings over two decades of healthcare investment banking expertise from firms like Cantor Fitzgerald. While the company does not utilize a traditional CTO title, technical leadership is spearheaded by Dr. Shaomeng Wang (Chief Scientific Advisor and Co-founder), a renowned Professor at the University of Michigan, and Dr. Chongdong Fu (SVP & Head of CMC). The board is bolstered by prominent figures such as Lead Independent Director Dr. David Sidransky of Johns Hopkins and R&D Committee Chair Dr. Marc E. Lippman. Notable institutional backing includes strategic investment from Takeda and significant positions held by Mirae Asset Global Investments and Citadel Advisors.